(bortezomib) in advanced multiple myeloma, and expects to have data
available in the third quarter of 2008.
-- In December 2007, HGS initiated dosing of approximately 105 patients in
a randomized Phase 2 trial of HGS-ETR1 in combination with paclitaxel
and carboplatin as first-line therapy in advanced non-small cell lung
cancer, and expects to have data available in 2009.
-- Today, HGS announced that it plans by mid-2008 to initiate a randomized
Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in
hepatocellular cancer. The study in hepatocellular cancer will begin
with a safety lead-in to assure the safety of this combination therapy
in patients with hepatocellular cancer who are infected with hepatitis
About the HGS IAP Inhibitor Program
In December 2007, the HGS oncology portfolio was further strengthened by a licensing and collaboration agreement between HGS and Aegera Therapeutics Inc. This agreement provides HGS with exclusive worldwide rights (excluding Japan) to develop and commercialize HGS1029 (formerly AEG40826) and other small- molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Preclinical studies of HGS1029 in combination with the Company's TRAIL receptor antibodies demonstrated dramatic synergistic activity against a number of cancer types. HGS1029 has also shown significant anti-tumor activity alone and in combination with other agents in a broad range of cancers. HGS expects to initiate a Phase 1 clinical trial of HGS1029 by mid-2008 and plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapeutic agents.
About HGS-ETR1 and HGS-ETR2
HGS-ETR1 and HGS-ETR2 are agonistic human monoclonal antibodies that
directly induce cancer-cell death by specifically binding to and activating
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved